Temporal spectrum of ischemic complications with percutaneous coronary intervention: The ESPRIT experience

Journal of Invasive Cardiology

Volumn 16, Issue 9, 2004, Pages 475-481

  Cantor, Warren J ^a   Tcheng, James E ^b   Blankenship, James C ^c   O'Shea, J Conor ^b   Pieper, Karen S ^b   Criger, Douglas A ^b   Madan, Mina ^d   Ducas, John ^e   Sheldon, William S ^f   Tannenbaum, Mark A ^g   Smith, Jack E ^h   Kitt, Michael M ⁱ   Gilchrist, Ian C ^j  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e HEALTH SCIENCES CENTRE   (Canada)

^f EMH Regional Medical Center   (United States)

^g Mercy Hospital Medical Center   (United States)

^h St Vincent's Hospital   (United States)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

^j PENNSYLVANIA STATE UNIVERSITY   (United States)

more..

Author keywords

Ischemia; Myocardial infarction; Stents

Indexed keywords

CREATINE KINASE; EPTIFIBATIDE;

ADULT; AGED; ARTICLE; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; CREATINE KINASE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HAZARD ASSESSMENT; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; REBOUND; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CREATINE KINASE; CREATINE KINASE, MB FORM; FEMALE; HUMANS; ISOENZYMES; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 4544367473     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Topol EJ and Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802-1820.
2. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
3. O'Shea JC, Madan M, Cantor WJ. Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. Am Heart J 2000;140:834-839.
4. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation. ESPRIT: A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, N Engl J Med 1994;330:956-961.
6. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
7. The IMPACT-11 Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention; IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-1428.
8. Lincoff AM, Topol EJ, Chapekis AT. Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: A matched case-control study. J Am Coll Cardiol 1993;21:866-875.
9. Schömig A, Kastrati A, Mudra H. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994;90:2716-2724,
10. Roubin GS, Cannon AD, Agrawal SK, Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-927.
11. George BS, Voorhees WD, Roubin GS. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes. J Am Coll Cardiol 1993;22:135-143.
12. Cantor WJ, Peterson ED, Popma JJ. Provisional stenting strategies: systematic overview and implications for clinical decision-making. J Am Coll Cardiol 2000;36:1142-1151.
13. Thel MC, Califf RM, Tardiff BE. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Am J Cardiol 2000;85:427-433.
14. Laperche T, Steg PG, Benessiano J. Patterns of myoglobin and MM creatlne kinase isoforms release early after intravenous thrombolysis or direct percutaneous transluminal coronaty angioplasty for acute myocardial infarction, and implications for the early noninvasive diagnosis of reperfusion. Am J Cardiol 1992;70:1129-1134.
15. Granger CB, Miller JM, Bovill EG. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935.
16. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ. Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation 1996;94:2083-2089.
17. O'Shea JC, Hafley GE, Greenberg S. Platelet glycoprotein IIb/IIIa Integrin blockade with eptifibatide in coronary stem intervention: The ESPRIT trial. A randomized controlled trial, J Am Med Assoc 2001;285:246S-2473.
18. Kern MJ, Deligonul U, Galan K. Percutaneous transluminal coronary angioplasty in octogenarians. Am J Cardiol 1988;61:457-458.
19. Buffet P, Danchin N, Juilliere Y. Percutaneous transluminal coronary angioplasty in patients more than 75 years old: Early and long-term results. Int J Cardiol 1992;37:33-39.
20. Simpfendorfer C, Raymond R, Schraider J, Early and long-term results of percutaneous transluminal coronary angioplasty in patients 70 years of age and older with angina pectoris. Am J Cardiol 1988;62:959-961.
21. Lincoff AM. Patients at high risk for ischemic complications. J Invas Cardiol 1994;6:13A-18A.
22. Tan K, Sulke H, Taub N. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. J Am Coll Cardiol 1995;25:855-865.
23. Ellis SG, Roubin GS, King SB III. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty, Circulation 1988;77:372-379.
24. Mabin TA, Holmes DR Jr., Smith HC. Intracoronary thrombus: Role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;5:198-202.
25. Detre KM, Holmes DR Jr., Holubkov R, Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry, Circulation 1990;82:739-750.
26. Brodie BR, Stuckey TD, Hansen C. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000;85:13-18.
27. Ellis SG, Vandormael MG, Cowley MJ. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Circulation 1990;82:1193-1202.
28. Topol EJ, Moliterno DJ, Hermann HC. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abxicimab, for the prevention of ischemic events with percutaneous coronary revascularization, N Engl J Med 2001;344:1888-1894.
29. Blankenship JC, Tasissa G, O'Shea JC, et al., the ESPRIT Investigators. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT rrial. J Am Coll Cardiol 2001;38:653-658.
30. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251.
31. Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999;33:88-96.